In the deep waters of digital transformation in the medical industry, Mindray is breaking the import monopoly with hardcore innovation, redefining the efficiency and accuracy of laboratory medicine. As a benchmark for domestic high-end total laboratory automation (TLA) production lines, the MT 8000 total laboratory intelligent production line has become the core choice for upgrading and transforming laboratory departments in medical institutions at all levels, injecting strong momentum into Mindray's high-quality growth with its impressive installation pace and solid clinical value.

Data is the most powerful proof. By 2025, the MT 8000 will have over 360 new domestic orders and nearly 270 new installations, with more than 20 installations overseas, covering international high-end clients such as the Jordan National Diabetes Center and several hospitals in Thailand. Entering 2026, the growth momentum is further released: in the first quarter, there were over 140 new domestic orders and more than 80 new installations; in March alone, installations exceeded 60, with an average of 2 installations per day, directly breaking the monthly installation record for domestic high-end TLA production lines.

As of now, nearly 600 MT 8000 units have been installed, and the installation structure shows high-quality characteristics—all are large TLA systems for biochemical immunology or multidisciplinary integrated production lines for coagulation and blood cell testing, excluding small cascade models. From national regional medical centers to top-tier hospitals and county medical communities, the MT 8000 is deeply penetrating diverse medical scenarios with its "production line first" strategy, becoming a true "installation king."

Laboratory departments choose equipment not based on gimmicks, but on usability, stability, and peace of mind. The MT 8000 is recognized precisely because it truly addresses the pain points of laboratory personnel: its high-throughput design easily handles peak sample flows, AI intelligent review significantly reduces burdens and increases efficiency, emergency processes are smooth and efficient, and quality control is reliable and traceable throughout. More importantly, the MT 8000 aligns with the new trends in laboratory medicine of "equipment + IT + AI" integration and "multidisciplinary integration," achieving multiple project testing from a single blood sample, reducing the number of blood draws for patients, and optimizing laboratory space and manpower allocation.

The popularity of the MT 8000 is not an isolated phenomenon but a reflection of Mindray's overall business resilience and growth. Although the domestic medical equipment industry is still in a weak recovery cycle, with domestic revenue reaching 3.903 billion yuan in the first quarter, Mindray is steadily increasing its market share in the in vitro diagnostics sector by continuously focusing on deep breakthroughs with major clients. The average market share for domestic immunology, biochemistry, and coagulation has increased from 10% in mid-2025 to 13% in the first quarter of this year; domestic revenue from in vitro diagnostics now accounts for half of total domestic revenue, with both immunology and coagulation businesses growing around 10% in the first quarter.

In the international market, the in vitro diagnostics business grew over 20% in the first quarter, with international immunology business growth exceeding 30%, and the initial results of over 20 MT 8000 installations overseas in 2025 are beginning to show. At the same time, domestic emerging businesses are experiencing strong growth momentum, with a year-on-year increase of over 18% in the first quarter, accounting for more than 70% of domestic revenue when combined with the in vitro diagnostics business, becoming an important foundation for driving growth. In the first quarter, the in vitro diagnostics production line achieved revenue of 3.193 billion yuan, a year-on-year increase of 4.96%, with its share of the company's overall revenue rising to 38%. New heavyweight products such as the BeneVision V series high-end monitors and the ultra-high-end ultrasound Resona A20 also achieved simultaneous volume growth Looking to the future, with the continued increase in the volume of MT 8000 reagents, Mindray's growth curve is becoming increasingly clear. The company expects that its domestic business will return to positive growth for the full year of 2026, and will enter a stable and high-quality continuous rapid growth channel from 2027 onwards. In the international market, thanks to the deeply built localized platform, the continuous increase in high-end products, and the successful bids for large-scale procurement projects, international business growth has significantly accelerated since the first quarter, and the globalization layout is opening up broader growth space.

From a production line to an ecosystem, from the domestic market to a global layout, Mindray is steadily advancing in the wave of digital intelligence with firm strategic determination and deep technological accumulation. As automation and intelligence continue to deepen, Mindray will continue to provide innovative solutions like MT 8000 to reduce burdens and increase efficiency in laboratories, improve testing quality, and make laboratory medicine more efficient, precise, and compassionate, contributing Chinese strength to the high-quality development of the global medical industry